semaglutide 7.2 mg clinical trial 2·4 once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo- controlled, phase 3 The FDA has approved a

You can view our partner Zion HealthShares current member guidelines here: Download April 2025 Member Guidelines Zion HealthShare Member Toolbox

Foundayo (Orforglipron) Foundayo represents the most recent addition to FDA-approved GLP-1 weight loss medications

Alcohol use disorder (AUD) is a medical condition marked by the inability to stop or control alcohol use

Dose ranges, reconstitution math, and titration schedules all differ

Since weight loss might alleviate these psychiatric comorbidities, it was reassuring to observe a reduced risk of suicidal behavior in the group treated with GLP1RAs." She added: "However, it is important to note that we cannot infer causality from our study design, and more research is needed to confirm these findings and explore potential mechanisms behind this association." It may be true that teenagers taking GLP-1 medication were less likely to experience suicidal thoughts because of the social stigma associated with obesity, alleviated by weight lossor, Kerem told Newsweek , it might be something more than this